Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CRG-022 |
| Synonyms | |
| Therapy Description |
CRG-022 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD22, which potentially induce tumor cell lysis (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CRG-022 | CRG 022|CRG022 | CD22 Immune Cell Therapy 13 | CRG-022 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD22, which potentially induce tumor cell lysis (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05972720 | Phase II | Cyclophosphamide + Fludarabine CRG-022 | A Phase 2 Study of CRG-022 in Patients With Relapsed/Refractory Large B-cell Lymphoma | Terminated | USA | 0 |